Concerns Over Opioid Access Tops AJPB Week in Review
Top news of the week from The American Journal of Pharmacy Benefits.
5. FDA Issues Special Protocol Agreement for Severe Bipolar Depression Treatment
NRX-101 is the first drug regimen designed to treat severe bipolar depression and acute suicidal ideation and behavior.
4. FDA OKs Therapy for BRAF Mutation-Positive Anaplastic Thyroid Cancer
The FDA approved Novartis’ combination treatment dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of BRAF V600 mutation-positive anaplastic thyroid cancer (ATC) that cannot be removed by surgery or is metastatic.
3. Experimental Drug Shows Promise in Schizophrenia
Treatment with RBP-7000 significantly reduced Positive and Negative Syndrome Scale (PANSS) total score and greatly increased the percentage of adults with schizophrenia achieving treatment response.
2. Substance Use Worsens Myocardial Infarction Outcomes
Adults that use marijuana and cocaine generally experience the worst possible outcomes of a myocardial infarction (MI), according to a recent study.
1. Easy Access to Opioids Among Main Concerns of Americans
More US adults believe that it is easy to get access to opioids for unlawful use, with millennials believing this more so than baby boomers.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025